.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after an average consequence of 11 months, people along with metastatic stomach cysts who received biomarker-matched therapies based on distributing lump DNA profiling revealed a higher medical benefit than those getting unequaled therapy.